Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Intrathecal nivolumab will be given at a flat dose of 40 mg

Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design.

Lumbar puncture for intrathecal delivery and collection of CSF

MRI Brain and full Spine (with and without contrast) will be performed prior to enrollment. During trial therapy, MRI Brain (with and without contrast) will be performed after cycle 1 and after that every 8 weeks (e.g. after cycle 3, cycle 5, etc…)